BioCentury | Apr 1, 2020
Distillery Therapeutics

Targeting curli amyloid fiber subunits csgA and csgB to treat Salmonella

DISEASE CATEGORY: Infectious disease INDICATION: Salmonella A mAb targeting a pan-amyloid epitope on Salmonella enterica csgA and csgB could treat infections by the bacteria by disrupting biofilm formation. In cultured, pre-established S. enterica biofilms, the...
BC Extra | Sep 12, 2019
Preclinical News

Sept. 12 Preclinical Quick Takes: Stephen Quake newco reveals epigenomic platform; plus Personal Genome, Summit and Biolife4D

Bluestar’s epigenomic platform IDs breast, pancreatic cancer  Bluestar Genomics Inc. (San Francisco, Calif.) showed it correctly identified breast and pancreatic cancers with areas under the curve of 0.89 and 0.95, respectively, with its machine learning...
BC Innovations | Jul 25, 2019
Distillery Therapeutics

Phenylisoxazole-quinoline-based DNA gyrase inhibitor for drug-resistant

DISEASE CATEGORY: Infectious disease INDICATION: Staphylococcus A phenylisoxazole-quinoline-based inhibitor of DNA gyrase could treat drug-resistant Staphylococcus aureus infections. In vitro , the compound inhibited S. aureus DNA gyrase supercoiling activity with an IC 50 of 85...
BioCentury | Apr 6, 2018
Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
BC Week In Review | Apr 6, 2018
Clinical News

Aradigm's Linhaliq under EMA review for lung infection

Aradigm Corp. (NASDAQ:ARDM) said EMA accepted for review an MAA for Linhaliq liposomal ciprofloxacin to treat non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic Pseudomonas aeruginosa lung infections. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights...
BC Extra | Apr 5, 2018
Company News

Aradigm's Linhaliq under EMA review for lung infection

Aradigm Corp. (NASDAQ:ARDM) said EMA accepted for review an MAA for Linhaliq liposomal ciprofloxacin to treat non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic Pseudomonas aeruginosa lung infections. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights...
BC Innovations | Apr 3, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus; Gram-positive bacterial infection Worm, cell culture and mouse studies suggest that retinoid antibiotics can help treat methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacterial infections. Screening of a library of synthetic small molecules...
BC Extra | Mar 28, 2018
Preclinical News

Brown researchers suggest retinoids as anti-MRSA antibiotic

In a paper published in Nature , researchers at Brown University and colleagues suggest that retinoids could be a new class of antibiotics, and developed an analog that could help treat methicillin-resistant Staphylococcus aureus infections. Drugs...
BC Week In Review | Mar 16, 2018
Clinical News

FDA approves label expansion for Otonomy's Otiprio

Otonomy Inc. (NASDAQ:OTIC) said FDA approved an sNDA for Otiprio ciprofloxacin to treat acute otitis externa due to Pseudomonas aeruginosa or Staphylococcus aureus infection in patients ages six months and older. Otiprio is a sustained-release...
BC Extra | Feb 14, 2018
Company News

Aradigm execs resign weeks after CRL

Aradigm Corp. (NASDAQ:ARDM) said President and CEO Igor Gonda, CMO Juergen Froehlich and CFO and VP of Finance Nancy Pecota resigned on Feb. 11, according to an SEC filing. The company named Chairman John Siebert...
Items per page:
1 - 10 of 296